Research and Development
Angelini has more than 40 years experience in research and development in the pharmaceutical sector, from the design of original molecules to their registration as drugs.
During its many years of research work, Angelini completely developed a number of drugs. Two of these, benzydamine, an anti-inflammatory agent for topical use, and trazodone, an antidepressant, are known all over the world and marketed in more than 60 countries. Recently, after buying the fluoroquinolone prulifloxacin licence from Nippon Shinyaku, Angelini carried out the full preclinical and clinical development of this new antibiotic, with registration and marketing in several European countries.
The Angelini research group has the necessary skills and facilities for sustaining the entire development of a drug, from the in silico models to the preclinical, formulative and clinical development, up to the registration and to pharmacovigilance activities.
This work is done at the Angelini Research Centre in S.Palomba, Rome, and at both public and private centres of scientific excellence, through cooperation with leading scientists worldwide.
At the moment, Angelini R&D is working on the development of new drugs, on the identification of new indications for drugs already on the market and on the expansion of its product line, making use of a high level of technological innovation. Side by side with the work of developing its pipeline, a Search & Development Team is working on the identification of potential partners whose scientific and
technical interests coincide with those of Angelini. Such partners are identified from among start-ups and academic research groups with a high scientific profile, in order to find the best licensing or partnership opportunities.
Angelini belongs to a working group called the Italian Drug Discovery Network (IDDN), which includes both other Italian pharmaceutical companies and public research institutes.
The aim of the IDDN is to promote interaction between public and private research in the identification of new pharmacologically active compounds.
Angelini research is actively involved in projects in the field of anti-infectives, together with other pharmaceutical companies, and it cooperates with university centres in studies on innovative molecular targets for pain and inflammation on molecules patented in academia.
In the field of studies on the CNS, cooperation is in progress with public research institutes for evaluating original molecules synthesized in the Angelini chemical laboratories.
Angelini Research and Development guarantees a high level of expertise and makes it possible to focus activities on research programmes in line with the company’s portfolio. Currently the main projects are related to the following therapeutic areas: pain/inflammation, CNS (mood disorders and insomnia), infectious diseases.
Focus on therapeutic areas
PAIN AND INFLAMMATION
Angelini R&D has a longstanding tradition of success with studies on pain and inflammation, areas that make a significant contribution to the company portfolio. The research subjects include studies on the role of prostaglandins, cytokines and serotoninergic transmission routes, in the mechanisms modulating pain and inflammation. Currently the R&D group is studying combinations of molecules or drugs active on the CNS that could increase their efficacy and reduce side effects. These studies also include optimization through formulative approaches in the bioavailability and posology of analgesic drugs.
CENTRAL NERVOUS SYSTEM (CNS)
The area of drugs active on the CNS, particularly drugs for mood disorders, is the field where Angelini has enjoyed the greatest successes and recognition at world level.
The introduction of the treatment of major depression into clinical practice, which happened in the USA during the Sixties and in 1981, changed the therapeutic approach to the treatment of this disease.
Trazodone is still used today, thanks to its broad spectrum of neurophysiopharmacological actions and its good tolerability.
All this made it possible to develop considerable expertise in the biochemistry, physiology and harmacology of the neural mechanisms involved in major depression and in other mood disorders. Even now, the Angelini laboratories continue making studies on the mechanisms of action of trazodone and on new compounds active on different molecular targets in neuropsychiatric diseases.
These studies deal with the problem of the mechanism responsible for the antidepressive activities following their effects on neurotransmission. Research activities are also in progress in the Angelini laboratories on new molecular targets responsible for the following pathologies of the CNS: bipolar disorder, schizophrenia, multiple sclerosis.
Starting with the experience of the development of prulifloxacin, Angelini R&D gradually became more interested in anti-infectives, an area where pharmacological research has become a priority in order to solve the serious problem of antibiotic resistance.
At present, studies are being made on the efficacy of different chemical classes (small molecules, macromolecules and peptides) and of medical devices made with advanced antibiotic-resistance technologies. Furthermore, Angelini R&D is tackling the emerging problem of the intestinal, vaginal and dermal microbiota, its role in maintaining the state of wellness and its alterations in infectious diseases.
Angelini R&D pipeline